Ambrisentan for the Treatment of Pulmonary Arterial Hypertension

20081,075 citationsJournal Article

Authors

Nazzareno Galiè · Justus-Liebig-Universität Gießen

Horst Olschewski · Justus-Liebig-Universität Gießen

Ronald J. Oudiz · Justus-Liebig-Universität Gießen

Ferràn Torres · Justus-Liebig-Universität Gießen

Adaani Frost · Justus-Liebig-Universität Gießen

Hossein Ardeschir Ghofrani · Justus-Liebig-Universität Gießen

David B. Badesch

Abstract

Ambrisentan improves exercise capacity in patients with pulmonary arterial hypertension. Improvements were observed for several secondary end points in each of the studies, although statistical significance was more variable. Ambrisentan is well tolerated and is associated with a low risk of aminotransferase abnormalities.

Topics & Keywords

Pulmonary Hypertension Research and Treatments Renin-Angiotensin System Studies Vascular Anomalies and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Circulation

Volume 117, Issue 23, pp. 3010-3019

DOI: 10.1161/circulationaha.107.742510

Field-Weighted Citation Impact: 63.45